Terminated PHASE3 INTERVENTIONAL 2-arm NCT00841945

Treatment of Aggressive Localized Lymphoma

Phase III Study of the Interest of Radiotherapy After 4 or 6 Cycles of CHOP 14 Rituximab Regimen of Chemotherapy , Patients With Agressive Localized Lymphoma

Sponsor: French Innovative Leukemia Organisation

Conditions B Cell Lymphoma

Interventions doxorubicin prednisone radiotherapy rituximab vincristine

Updated 5 times since 2017 Last updated: Feb 20, 2017 Started: Apr 30, 2005 Primary completion: Jan 31, 2016 Completion: Feb 28, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

other drugs other studies

Other terminated trials from French Innovative Leukemia Organisation

See all terminations from French Innovative Leukemia Organisation

Other B Cell Lymphoma trials with similar outcome

Browse all B Cell Lymphoma trials

A PHASE3 clinical study on B Cell Lymphoma, this trial is terminated or withdrawn. The trial is conducted by French Innovative Leukemia Organisation and has accumulated 5 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE3

First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

French Innovative Leukemia Organisation

Data source: French Innovative Leukemia Organisation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rennes, France